COMPANY RESEARCHBristol-Myers Squibb Company
Bristol Myers Squibb is a U.S. biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its therapeutic platforms include small-molecule drugs, biologic medicines and cell therapies, supported by internal research and external collaborations. Key areas of focus include oncology, immunology and cardiovascular disease. The company's common shares trade on the New York Stock Exchange under BMY. As a global pharmaceutical developer, it operates across multiple stages of research, clinical evaluation and commercial supply.
Company at a glance
Corporate information
- Company entity
- Bristol Myers Squibb Group（formed through a merger in 1989）
- Headquarters / principal office
- Princeton, New Jersey, USACorporate website explicitly identifies headquarters; location follows the retrieved disclosure.
Sources (1)
- Official company contact / corporate location disclosureChecked 2026-11-04; source publication date retained where stated
- Founded
- 1989
Sources (2)
- BMS Company History TimelineNot stated
- BMS FY2024 Form10-K2025-02
- Ownership / capital status
- Publicly tradedPublicly traded (group)
Sources (2)
- Bristol Myers Squibb company profileNot stated
- BMS FY2024 Form10-K2025-02
- Official corporate reference
- https://www.bms.com/
Sources (1)
- BMS Company History TimelineNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Bristol Myers Squibb - Global Biopharmaceutical CompanyAccessed 2026-11-04; undated unless stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Bristol Myers Squibb is a U.S. biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its therapeutic platforms include small-molecule drugs, biologic medicines and cell therapies, supported by internal research and external collaborations. Key areas of focus include oncology, immunology and cardiovascular disease. The company's common shares trade on the New York Stock Exchange under BMY. As a global pharmaceutical developer, it operates across multiple stages of research, clinical evaluation and commercial supply.
NYSE: BMY
small molecules · biologics · cell therapies
oncology · immunology · cardiovascular
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
On 2026-08-13, FDA granted accelerated approval to iberdomide (Zenbexus) with daratumumab/hyaluronidase-fihj and dexamethasone for certain previously treated multiple myeloma patients. It is a CRBN-modulating CELMoD.
Business, technology & evidence
- Bristol Myers Squibb is a U.S. biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its therapeutic platforms include small-molecule drugs, biologic medicines and cell therapies, supported by internal research and external collaborations. Key areas of focus include oncology, immunology and cardiovascular disease. The company's common shares trade on the New York Stock Exchange under BMY. As a global pharmaceutical developer, it operates across multiple stages of research, clinical evaluation and commercial supply.
- SecuritiesNYSE: BMY
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| iberdomide / ZENBEXUS | IKZF1/IKZF3（CRBN） · Multiple myeloma after at least one prior line containing a proteasome inhibitor and an immunomodulatory drug; IberDd combination (U.S. accelerated approval) | Approved | FDA accelerated approval; confirmatory clinical benefit required |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Accelerated approval requires confirmation of clinical benefit; this record does not imply approval of all new degradation programs.
- FDA grants accelerated approval to iberdomide ↗FDA · 2026-08-13
- Iberdomide Clinical Inspection Summary ↗FDA · 2026
- Official issuer and R&D disclosure · Bristol-Myers Squibb Company ↗Bristol-Myers Squibb Company ·
- Official issuer and R&D disclosure · Bristol-Myers Squibb Company ↗Bristol-Myers Squibb Company ·
- Official issuer and R&D disclosure · Bristol-Myers Squibb Company ↗Bristol-Myers Squibb Company ·
- BMS Company History Timeline ↗Bristol Myers Squibb · Not stated
- Bristol Myers Squibb company profile ↗BMS / LinkedIn · Not stated
- BMS FY2024 Form10-K ↗BMS / SEC · 2025-02
- Official company contact / corporate location disclosure ↗Bristol Myers Squibb · Checked 2026-11-04; source publication date retained where stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.